BioSpace News Archive

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during ongoing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19.

Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported today its 2020 H1 financial results and provided a corporate update. " At Ryvu, we always excelled in moving forward at a rapid pace; however, the first half

NEXGEL, Inc., an innovative company developing ultra-gentle, high-water content E-beam hydrogels with a focus on the consumer over-the-counter, Rx, medical device and cosmetic markets, announced that they have begun the launch of several proprietary products utilizing their hydrogel technology for various indications.

According to the report, the global endodontic consumables market was valued at ~US$ 1.1 Bn in 2018. It is projected to expand at a CAGR of ~5% from 2019 to 2027.

Additional research will highlight findings in colorectal and gastrointestinal cancers that could impact treatment decisions for patients

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has dosed the first subjects in a Phase 1 trial of aTyr’s lead therapeutic candidate ATYR1923.

Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced the appointment of industry veteran and oncologist, Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer.

FDA to Require a Single Phase 3 Trial of 12 Weeks Duration to Support Efficacy for an NDA filing in SHTG

AnPac Bio-Medical Science Co., Ltd. announced that the Company entered into a noteworthy sales contract in mid-August 2020 with Beijing Yuan Jian Health Management Co., Ltd. in China for the Company’s newly launched immunology test, AnPac Defense Medical Examination.

A new clinical trial funded by the Canadian Cancer Society in partnership with the Canadian Institutes of Health Research is testing a promising treatment to repair brain injury and improve quality of life in survivors of childhood brain cancer.